ArticleClinical and translational radiation oncology2021
Analysis of the electron-stream effect in patients treated with partial breast irradiation using the 1.5 T MR-linear accelerator.
Article in Clinical and translational radiation oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 18 citations in OpenAlex.
- Feasibility of segmental total body irradiation (SegTBI) using a 1.5T MR-linac.Journal of applied clinical medical physics · 2025Article
- Study protocol: Optimising patient positioning for the planning of accelerated partial breast radiotherapy for the integrated magnetic resonance linear accelerator: OPRAH MRL.Radiation oncology (London, England) · 2024Article
- Electron streaming dose measurements and calculations on a 1.5 T MR-Linac.Journal of applied clinical medical physics · 2024Article
- Adaptive radiotherapy for breast cancer.Clinical and translational radiation oncology · 2023Review
- Electron stream effect in 0.35 Tesla magnetic resonance image guided radiotherapy for breast cancer.Frontiers in oncology · 2023Article
- Practical guidelines of online MR-guided adaptive radiotherapy.Journal of radiation research · 2022Article
- Estimation of secondary cancer projected risk after partial breast irradiation at the 1.5 T MR-linac.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2022Article
- Characterizing magnetically focused contamination electrons by off-axis irradiation on an inline MRI-Linac.Journal of applied clinical medical physics · 2022Article
- Magnetic-Field-Induced Secondary-Electron Effects in MR-Guided Radiotherapy: From Dosimetric Mechanisms to Workflow-Based Clinical Risk Management.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe hybrid magnetic resonance linear accelerator (MRL) has the potential to test novel concepts in breast cancer patients such as daily MR-guided real-time plan adaptation. Before starting clinical trials, preparatory studies for example of the MR-dependent electron stream effect (ESE) are necessary. MATERIAL AND
methodsTo prospectively investigate the ESE, data from 11 patients treated with partial breast irradiation (PBI) at the 1.5 T MRL were evaluated. A bolus was placed on the chin and
resultsMedian doses measured and simulated on top/ underneath the bolus were 1.91 / 0.62 Gy and 2.82 / 0.63 Gy, respectively. Median differences between calculations and measurements were 0.8 Gy and 0.1 Gy. At the conventional linac, median measured doses on top/ underneath the bolus were 0.98 and 1.37 Gy. No acute toxicity exceeding grade 2 was recorded. Cosmesis was good or excellent and patient reported outcome measures were mostly scored as none or mild.
conclusionThe dose due to the ESE is low, correctly predicted by the TPS and effectively minimized by a bolus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.